These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2021304)

  • 1. Desensitization of terminal 5-HT autoreceptors by 5-HT reuptake blockers.
    de Montigny C; Blier P
    Arch Gen Psychiatry; 1991 May; 48(5):483-4. PubMed ID: 2021304
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain.
    Savage DD; Frazer A; Mendels J
    Eur J Pharmacol; 1979 Sep; 58(1):87-8. PubMed ID: 315323
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain.
    Blier P; Chaput Y; de Montigny C
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Mar; 337(3):246-54. PubMed ID: 3260661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential antidopaminergic effects of serotonin reuptake inhibitors.
    Kim SW; Dysken MW
    J Clin Psychiatry; 1991 Jan; 52(1):42. PubMed ID: 1988420
    [No Abstract]   [Full Text] [Related]  

  • 5. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
    Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
    Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sensitivity of cortical neurons to serotonin: effect of chronic treatment with antidepressants, serotonin-uptake inhibitors and monoamine-oxidase-blocking drugs.
    Olpe HR; Schellenberg A
    J Neural Transm; 1981; 51(3-4):233-44. PubMed ID: 6793695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase inhibitors and serotonin uptake inhibitors: differential effects on [3H]serotonin binding sites in rat brain.
    Savage DD; Mendels J; Frazer A
    J Pharmacol Exp Ther; 1980 Feb; 212(2):259-63. PubMed ID: 7351637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder.
    Fernández-Guasti A; Ulloa RE; Nicolini H
    Psychopharmacology (Berl); 2003 Mar; 166(3):195-201. PubMed ID: 12589517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence.
    Blier P; de Montigny C; Chaput Y
    J Clin Psychiatry; 1990 Apr; 51 Suppl():14-20; discussion 21. PubMed ID: 2157700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
    Murphy DL; Zohar J; Benkelfat C; Pato MT; Pigott TA; Insel TR
    Br J Psychiatry Suppl; 1989 Dec; (8):15-24. PubMed ID: 2692636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.
    Insel TR; Murphy DL; Cohen RM; Alterman I; Kilts C; Linnoila M
    Arch Gen Psychiatry; 1983 Jun; 40(6):605-12. PubMed ID: 6342562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychopharmacology of drugs effective in obsessive-compulsive disorder.
    Taniguchi G
    J Clin Psychopharmacol; 1988 Feb; 8(1):71. PubMed ID: 3351005
    [No Abstract]   [Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors in OCD.
    Montgomery SA; Bullock T; Fineberg N; Montgomery D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():255A-256A. PubMed ID: 1498831
    [No Abstract]   [Full Text] [Related]  

  • 14. Symptom relapse in bulimia nervosa and obsessive compulsive disorder after treatment with serotonin antagonists.
    Hollander E; Mullen LS; Carrasco JL; DeCaria CM; Stein DJ
    J Clin Psychiatry; 1992 Jan; 53(1):28. PubMed ID: 1737737
    [No Abstract]   [Full Text] [Related]  

  • 15. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
    Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR
    Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models in obsessive compulsive disorder.
    Olivier B
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():27-9. PubMed ID: 1517553
    [No Abstract]   [Full Text] [Related]  

  • 17. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of depersonalization with serotonin reuptake blockers.
    Hollander E; Liebowitz MR; DeCaria C; Fairbanks J; Fallon B; Klein DF
    J Clin Psychopharmacol; 1990 Jun; 10(3):200-3. PubMed ID: 2115893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of serotonin antagonists in depressive disorders.
    Wood MD; Thomas DR; Watson JM
    Expert Opin Investig Drugs; 2002 Apr; 11(4):457-67. PubMed ID: 11922855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder.
    Benkert O; Wetzel H; Szegedi A
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():3-14. PubMed ID: 8254151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.